Biotechnologically produced collagen in dietary supplements

GELITA & Geltor sign Memorandum of Understanding on Marketing

24-Oct-2019 - Germany

During Supply Side West (SSW) Expo, one of the leading food and health fairs in the USA, representatives of GELITA and Geltor signed a Memorandum of Understanding to develop, manufacture and market the first consumable biotech collagen proteins. Commercial marketing is planned for the end of 2020. Under the terms of the agreement, Geltor will develop and manufacture the premium collagen biotechnologically, while GELITA will conduct the necessary clinical studies on its efficacy and then commercialize it in addition to its existing collagen portfolio.

GELITA, the leader in the global collagen protein market, is the first collagen producer to believe in the huge potential of biotechnological collagen peptides and to invest heavily in Geltor. In the next step, GELITA will become an active partner in the development, research and marketing of next-generation collagen ingredients.

Geltor, a biodesign company that produces high-quality designer proteins through fermentation, is the first company to open up the market for animal-free collagen. It is the first company to launch a portfolio of award-winning animal-free protein ingredients for the skin care market: Collume[TM], a marine animal-based collagen; and HumaColl21[TM], a human-based collagen. The agreement with GELITA marks the beginning of the Californian company's expansion into the food and beverage market.

GELITA collagen peptides are recording double-digit growth worldwide. As a pioneer in the clinical research and production of collagen peptides, GELITA is optimistic about a successful commercialization of its proprietary product platform for the first consumable biotechnologically produced collagens.

Hans-Ulrich Frech, Global VP of the Collagen Peptides Business Unit at GELITA, said: "GELITA's decision to invest in biotechnology is an excellent example of our commitment to innovation and understanding market needs. Frech continued that the forthcoming expansion of the portfolio to include non-animal collagen peptides will further strengthen GELITA's position as market leader and enable the satisfaction of various markets in which vegan products are in demand. This addition to GELITA's collagen portfolio complements the already solid portfolio of scientifically based bioactive collagen peptides®, which are important components of foods and dietary supplements due to their protein content and physiological benefits".

Geltor CEO and co-founder Alexander Lorestani added: "This agreement confirms our belief that we have ushered in a new era of using proteins to improve products that consumers around the world use every day. Today, the market is ready for premium offers of protein ingredients and this is the demand that Geltor serves. We are delighted to be working with GELITA to deliver the next generation of collagen to consumers. For a relatively young and fast-growing company like Geltor, the partnership with GELITA and its long history of success with a business of this size and reach is a dream come true.

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.

https://www.yumda.com/en/news/1163371/biotechnologically-produced-collagen-in-dietary-supplements.html